Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
This will be Aster’s fifth hospital in Bengaluru
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
cSCC is one of the most common cancers in the U.S. and globally
Subscribe To Our Newsletter & Stay Updated